RNA-Seq Identifies Circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as Potential Biomarkers for Acute Ischemic Stroke

Rationale: Currently, there are no blood-based biomarkers with clinical utility for acute ischemic stroke (IS). MicroRNAs show promise as disease markers because of their cell type–specific expression patterns and stability in peripheral blood. Objective: To identify circulating microRNAs associated with acute IS, determine their temporal course up to 90 days post-stroke, and explore their utility as an early diagnostic marker. Methods and Results: We used RNA sequencing to study expression changes of circulating microRNAs in a discovery sample of 20 patients with IS and 20 matched healthy control subjects. We further applied quantitative real-time polymerase chain reaction in independent samples for validation (40 patients with IS and 40 matched controls), replication (200 patients with IS, 100 healthy control subjects), and in 72 patients with transient ischemic attacks. Sampling of patient plasma was done immediately upon hospital arrival. We identified, validated, and replicated 3 differentially expressed microRNAs, which were upregulated in patients with IS compared with both healthy control subjects (miR-125a-5p [1.8-fold; P=1.5×10−6], miR-125b-5p [2.5-fold; P=5.6×10−6], and miR-143-3p [4.8-fold; P=7.8×10−9]) and patients with transient ischemic attack (miR-125a-5p: P=0.003; miR-125b-5p: P=0.003; miR-143-3p: P=0.005). Longitudinal analysis of expression levels up to 90 days after stroke revealed a normalization to control levels for miR-125b-5p and miR-143-3p starting at day 2 while miR-125a-5p remained elevated. Levels of all 3 microRNAs depended on platelet numbers in a platelet spike-in experiment but were unaffected by chemical hypoxia in Neuro2a cells and in experimental stroke models. In a random forest classification, miR-125a-5p, miR-125b-5p, and miR-143-3p differentiated between healthy control subjects and patients with IS with an area under the curve of 0.90 (sensitivity: 85.6%; specificity: 76.3%), which was superior to multimodal cranial computed tomography obtained for routine diagnostics (sensitivity: 72.5%) and previously reported biomarkers of acute IS (neuron-specific enolase: area under the curve=0.69; interleukin 6: area under the curve=0.82). Conclusions: A set of circulating microRNAs (miR-125a-5p, miR-125b-5p, and miR-143-3p) associates with acute IS and might have clinical utility as an early diagnostic marker.

[1]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[2]  C. Sommer Ischemic stroke: experimental models and reality , 2017, Acta Neuropathologica.

[3]  Ashutosh Kumar Singh,et al.  Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.

[4]  M. Mayr,et al.  Association of MicroRNAs and YRNAs With Platelet Function. , 2016, Circulation research.

[5]  J. McClure,et al.  MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension. , 2015, Circulation research.

[6]  Taek-Kyun Kim,et al.  Current State of Circulating MicroRNAs as Cancer Biomarkers. , 2015, Clinical chemistry.

[7]  Meng Li,et al.  Circulating MicroRNAs: Potential and Emerging Biomarkers for Diagnosis of Cardiovascular and Cerebrovascular Diseases , 2015, BioMed research international.

[8]  S. Engelhardt,et al.  Intercellular miRNA Traffic. , 2015, Circulation research.

[9]  G. Condorelli,et al.  TGFβ Triggers miR-143/145 Transfer From Smooth Muscle Cells to Endothelial Cells, Thereby Modulating Vessel Stabilization. , 2015, Circulation research.

[10]  M. Weirauch,et al.  MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis , 2015, Nature Communications.

[11]  Chunbing Zhang,et al.  Identification of Circulating MicroRNAs as Potential Biomarkers for Detecting Acute Ischemic Stroke , 2014, Cellular and Molecular Neurobiology.

[12]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[13]  Jun Liu,et al.  miR-125a-5p impairs endothelial cell angiogenesis in aging mice via RTEF-1 downregulation , 2014, Aging cell.

[14]  S. Luo,et al.  Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study , 2014, Nature Methods.

[15]  Krzysztof Fujarewicz,et al.  Analysis options for high-throughput sequencing in miRNA expression profiling , 2014, BMC Research Notes.

[16]  Stefan Hüttelmaier,et al.  Rapid identification of regulatory microRNAs by miTRAP (miRNA trapping by RNA in vitro affinity purification) , 2014, Nucleic acids research.

[17]  E. Abraham,et al.  miR-125a-5p Regulates Differential Activation of Macrophages and Inflammation* , 2013, The Journal of Biological Chemistry.

[18]  C. Hamm,et al.  Release kinetics of circulating muscle-enriched microRNAs in patients undergoing transcoronary ablation of septal hypertrophy. , 2013, Journal of the American College of Cardiology.

[19]  P. Tsai,et al.  Serum microRNA-21 and microRNA-221 as Potential Biomarkers for Cerebrovascular Disease , 2013, Journal of Vascular Research.

[20]  Mary G. George,et al.  An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[21]  M. Mayr,et al.  Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease , 2013, Thrombosis and Haemostasis.

[22]  J. Kessler,et al.  The emerging roles of microRNAs in CNS injuries , 2013, Nature Reviews Neurology.

[23]  K. Witwer,et al.  Comparison of Methods for miRNA Extraction from Plasma and Quantitative Recovery of RNA from Cerebrospinal Fluid , 2013, Front. Genet..

[24]  H. D. de Vries,et al.  MicroRNAs Regulate Human Brain Endothelial Cell-Barrier Function in Inflammation: Implications for Multiple Sclerosis , 2013, The Journal of Neuroscience.

[25]  Max Wintermark,et al.  Computed Tomography Workup of Patients Suspected of Acute Ischemic Stroke: Perfusion Computed Tomography Adds Value Compared With Clinical Evaluation, Noncontrast Computed Tomography, and Computed Tomography Angiogram in Terms of Predicting Outcome , 2013, Stroke.

[26]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[27]  M. Mayr,et al.  MicroRNAs Within the Continuum of Postgenomics Biomarker Discovery , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[28]  H. Kidoya,et al.  microRNA-125b inhibits tube formation of blood vessels through translational suppression of VE-cadherin , 2013, Oncogene.

[29]  M. Mayr,et al.  Circulating MicroRNAs as Novel Biomarkers for Platelet Activation , 2013, Circulation research.

[30]  M. Mayr,et al.  Prospective study on circulating MicroRNAs and risk of myocardial infarction. , 2012, Journal of the American College of Cardiology.

[31]  Anton P. McCaffrey,et al.  Identifying Functional MicroRNAs in Macrophages with Polarized Phenotypes* , 2012, The Journal of Biological Chemistry.

[32]  A. Tijsen,et al.  Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? , 2012, Circulation research.

[33]  Manuel Mayr,et al.  MicroRNAs in vascular and metabolic disease. , 2012, Circulation research.

[34]  M. Mayr,et al.  Profiling of circulating microRNAs: from single biomarkers to re-wired networks , 2011, Cardiovascular research.

[35]  S. Luo,et al.  RNA-ligase-dependent biases in miRNA representation in deep-sequenced small RNA cDNA libraries. , 2011, RNA.

[36]  K. Anstrom,et al.  Discriminative capacity of biomarkers for acute stroke in the emergency department. , 2011, The Journal of emergency medicine.

[37]  R. Dengler,et al.  The Temporal Profile of Inflammatory Markers and Mediators in Blood after Acute Ischemic Stroke Differs Depending on Stroke Outcome , 2010, Cerebrovascular Diseases.

[38]  Ting-Yim Lee,et al.  Certainty of stroke diagnosis: incremental benefit with CT perfusion over noncontrast CT and CT angiography. , 2010, Radiology.

[39]  P. Sharp,et al.  Regulation of Synaptic Structure and Function by FMRP-Associated MicroRNAs miR-125 b and miR-132 , 2010 .

[40]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[41]  K. Tan,et al.  Expression Profile of MicroRNAs in Young Stroke Patients , 2009, PloS one.

[42]  P. Tam Faculty Opinions recommendation of miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. , 2009 .

[43]  Deepak Srivastava,et al.  miR-145 and miR-143 Regulate Smooth Muscle Cell Fate Decisions , 2009, Nature.

[44]  M. Sitzer,et al.  Characterisation of the Diagnostic Window of Serum Glial Fibrillary Acidic Protein for the Differentiation of Intracerebral Haemorrhage and Ischaemic Stroke , 2008, Cerebrovascular Diseases.

[45]  Peter Sandercock,et al.  Blood Biomarkers in the Diagnosis of Ischemic Stroke: A Systematic Review , 2008, Stroke.

[46]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[47]  M. Wunderlich,et al.  Release of glial fibrillary acidic protein is related to the neurovascular status in acute ischemic stroke , 2006, European journal of neurology.

[48]  T. Neumann-Haefelin,et al.  Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. , 2005, Archives of neurology.

[49]  J. Wardlaw,et al.  Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment--systematic review. , 2005, Radiology.

[50]  L. Stead,et al.  Neuron-Specific Enolase as a Marker for Acute Ischemic Stroke: A Systematic Review , 2004, Cerebrovascular Diseases.

[51]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[52]  N. Rothwell,et al.  Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome , 2004, BMC neurology.

[53]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[54]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[55]  M. F. Stewart,et al.  Heparin Selectively Affects the Quantification of MicroRNAs in Human Blood Samples , 2013 .

[56]  A. González-Quevedo,et al.  Serum neuron-specific enolase and S100 calcium binding protein B biomarker levels do not improve diagnosis of acute stroke. , 2012, The journal of the Royal College of Physicians of Edinburgh.

[57]  Andy Liaw,et al.  Classification and Regression by randomForest , 2007 .

[58]  T. Neumann-Haefelin,et al.  Evaluation of Serum S 100 B as a Surrogate Marker for Long-term Outcome and Infarct Volume in Acute Middle Cerebral Artery Infarction , 2005 .